Volume 31, Number 8—August 2025
Dispatch
Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023
, Jeremy A.W. Gold, Kaitlin Forsberg, Sophie Jones, and Meghan M. Lyman
Table 2
Patients with Candida auris screening cases with progression to clinical case status, by body site of clinical case detection, United States, 2016–2023*
| Characteristic | All, N = 1,458 | Blood, n = 584 | Urine, n = 391 | Respiratory, n = 233 | Wound, n = 168 | Other, n = 82† | p value‡ |
|---|---|---|---|---|---|---|---|
| Median age at collection of screening case specimen, y (IQR), n = 1,238 |
67 (59–76) |
68 (60–76) |
68 (58–77) |
68 (60–77) |
67 (61–75) |
64 (50–71) |
0.023 |
| Age group at collection of screening case specimen, y, n = 1,238 | 0.027 | ||||||
| <45 | 118 | 42 (35.6) | 40 (33.9) | 8 (6.8) | 15 (12.7) | 13 (11.0) | |
| 45–54 | 105 | 35 (33.3) | 27 (25.7) | 21 (20.0) | 11 (10.5) | 11 (10.5) | |
| 55–64 | 279 | 106 (38.0) | 69 (24.7) | 55 (19.7) | 38 (13.6) | 11 (3.9) | |
| 65–74 | 368 | 134 (36.4) | 97 (26.4) | 68 (18.5) | 48 (13.0) | 21 (5.7) | |
| 75–84 | 274 | 106 (38.7) | 83 (30.3) | 43 (15.7) | 31 (11.3) | 11 (4.0) | |
| >85 |
94 |
33 (35.1) |
26 (27.7) |
22 (23.4) |
12 (12.8) |
1 (1.1) |
|
| Sex, n = 1,183 | <0.001 | ||||||
| M | 671 | 215 (32.0) | 216 (32.2) | 124 (18.5) | 76 (11.3) | 40 (6.0) | |
| F |
512 |
218 (42.6) |
110 (21.5) |
84 (16.4) |
73 (14.3) |
27 (5.3) |
|
| Antimicrobial Resistance Laboratory Network region of the facility of specimen collection for clinical case§ | <0.001 | ||||||
| West | 898 | 306 (34.1) | 252 (28.1) | 173 (19.3) | 124 (13.8) | 43 (4.8) | |
| Midwest | 96 | 24 (25.0) | 36 (37.5) | 22 (22.9) | 8 (8.3) | 6 (6.3) | |
| Southeast | 56 | 33 (58.9) | 10 (17.9) | 7 (12.5) | 3 (5.4) | 3 (5.4) | |
| Northeast | 302 | 177 (58.6) | 68 (22.5) | 25 (8.3) | 20 (6.6) | 12 (4.0) | |
| Mid-Atlantic | 64 | 37 (57.8) | 11 (17.2) | 3 (4.7) | 4 (6.3) | 9 (14.1) | |
| Mountain | 42 | 7 (16.7) | 14 (33.3) | 3 (7.1) | 9 (21.4) | 9 (21.4) | |
| Central¶ |
0 |
0 (NA) |
0 (NA) |
0 (NA) |
0 (NA) |
0 (NA) |
|
| No. days from collection date of first positive screening to first clinical case specimen# | 0.001 | ||||||
| Median (IQR) | 46 (19–108) | 58 (22–130) | 44 (20–120) | 33 (17–74) | 44 (17–91) | 28 (14–77) | |
| Minimum–maximum | 1–1,597 | 1–1,309 | 1–1,597 | 1–1,240 | 1–666 | 1–745 | |
*Values are no. (%) except as indicated. IQR, interquartile range; NA, not applicable. †Other specimen type included device (n = 14), fluid/drainage (n = 5), intraabdominal (n = 2), other (n = 60), and unknown (n = 1). ‡p values were calculated using χ2 tests (categorical variables) or Kruskal-Wallis rank-sum test (continuous variables) to compare features of interest by body site. §https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/domestic.html. Data from 2023 were unavailable from 1 state in the Central region. ¶Row excluded from p value calculations because no screening-to-clinical cases were reported in the Central region. #Data missing for 1 patient with a clinical case involving a wound.